1208 ecp tallac
BioCentury & Getty Images

Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

Emerging Company Profile: Tallac launches with $62M A round, pipeline of antibody-TLR9 agonist conjugates

Tallac has launched with a $62 million series A round and a solid tumor platform enabling I.V. administration of immunostimulatory TLR9 agonist via conjugation to antibodies.

Dec 9, 2020 | 1:24 AM GMT

Tallac

Read the full 606 word article

How to gain access

Continue reading with a
two-week free trial.